Results 31 to 40 of about 28,496 (220)

Genetics of Myeloproliferative Neoplasms [PDF]

The Cancer Journal, 2014
In the last decade, genomic studies have identified multiple recurrent somatic mutations in myeloproliferative neoplasms (MPNs). Beginning with the discovery of the JAK2 V617F mutation, multiple additional mutations have been found that constitutively activate cell-signaling pathways, including MPL, CBL, and LNK.
Aaron D, Viny, Ross L, Levine
openaire   +2 more sources

Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis

Frontiers in Oncology, 2020
Numerous studies have documented ultrastructural abnormalities in malignant megakaryocytes from bone marrow (BM) of myelofibrosis patients but the morphology of these cells in spleen, an important extramedullary site in this disease, was not investigated
Maria Zingariello, Vittorio Rosti, Alessandro M. Vannucchi, Paola Guglielmelli, Maria Mazzarini, Giovanni Barosi, Maria Luisa Genova, Anna Rita Migliaccio, Anna Rita Migliaccio   +8 more
doaj   +1 more source

Pathogenesis of myeloproliferative neoplasms

Experimental Hematology, 2015
Major progress has been recently made in understanding the molecular pathogenesis of myeloproliferative neoplasms (MPN). Mutations in one of four genes-JAK2, MPL, CALR, and CSF3R-can be found in the vast majority of patients with MPN and represent driver mutations that can induce the MPN phenotype.
Skoda, Radek C., Duek, Adrian, Grisouard, Jean   +2 more
openaire   +4 more sources

Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms

Haematologica, 2010
Somatic activating mutations in MPL, the thrombopoietin receptor, occur in the myeloproliferative neoplasms, although virtually nothing is known about their role in evolution to acute myeloid leukemia. In this study, the MPL T487A mutation, identified in
Philip A. Beer, Christina A. Ortmann, Frank Stegelmann, Paola Guglielmelli, John T. Reilly, Thomas S. Larsen, Hans C. Hasselbalch, Alessandro M. Vannucchi, Peter Möller, Konstanze Döhner, Anthony R. Green   +10 more
doaj   +1 more source

Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency

Haematologica, 2016
Juvenile myelomonocytic leukemia is a rare myeloproliferative neoplasm characterized by hyperactive RAS signaling. Neurofibromin1 (encoded by the NF1 gene) is a negative regulator of RAS activation.
Zohar Sachs, Raha A. Been, Krista J. DeCoursin, Hanh T. Nguyen, Nurul A. Mohd Hassan, Klara E. Noble-Orcutt, Craig E. Eckfeldt, Emily J. Pomeroy, Ernesto Diaz-Flores, Jennifer L. Geurts, Miechaleen D. Diers, Diane E. Hasz, Kelly J. Morgan, Margaret L. MacMillan, Kevin M. Shannon, David A. Largaespada, Stephen M. Wiesner   +16 more
doaj   +1 more source

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

Molecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge, Morten Tulstrup, Gabriele Todisco, Pedro Moura, Christophe Côme, Jakob Werner Hansen, Jakob Schmidt Jespersen, Balthasar Schlotmann, Maria Creignou, Mette Dahl, Claudia Schöllkopf, Klas Raaschou‐Jensen, Krister Wennerberg, Bo Porse, Joachim Weischenfeldt, Eva Hellström‐Lindberg, Lasse Sommer Kristensen, Kirsten Grønbæk   +17 more
wiley   +1 more source

Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome

Haematologica, 2017
Chronic eosinophilic leukemia, not otherwise specified can be difficult to distinguish from idiopathic hypereosinophilic syndrome according to the current World Health Organization guideline.
Sa A. Wang, Robert P. Hasserjian, Wayne Tam, Albert G. Tsai, Julia T. Geyer, Tracy I. George, Kathryn Foucar, Heesun J. Rogers, Eric D. Hsi, Bryan A. Rea, Adam Bagg, Carlos E. Bueso-Ramos, Daniel A. Arber, Srdan Verstovsek, Attilio Orazi   +14 more
doaj   +1 more source

Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders – Epidemiological Features and Overview

Frontiers in Oncology, 2021
The WHO-category Myelodysplastic/Myeloproliferative neoplasms (MDS/MPNs) recognizes a unique group of clonal myeloid malignancies exhibiting overlapping features of myelodysplastic as well as myeloproliferative neoplasms.
Andrea Kuendgen, Annika Kasprzak, Ulrich Germing   +2 more
doaj   +1 more source

GelMA‐based 3D spheroids recapitulate transcriptomic and functional hallmarks of myeloid sarcoma

FEBS Open Bio, EarlyView.
GelMA 5% hydrogels support the formation of myeloid leukemia spheroids that recapitulate MS‐specific features, including G1 arrest, apoptosis, and ECM‐driven transcriptomic reprogramming. The 3D model mimicked soft‐tissue‐like stiffness and oxygen conditions, and transcriptomic convergence with primary MS samples confirmed its utility as a preclinical ...
Nicolas Germain, Elise Buret, Le Hoang Thanh Nguyen, Marion Cocheteux, Nicolas Touya, Mélanie Dhayer, Romain Dubois, Frank Lafont, Sebastien Janel, Patrice Maboudou, Steve Lancel, Philippe Marchetti   +11 more
wiley   +1 more source

Histopathology imagery dataset of Ph-negative myeloproliferative neoplasm

Data in Brief, 2023
Tumorous cancer has been a widely known and well-studied medical phenomenon; however, rare diseases like Myeloproliferative Neoplasm (MPN) have received less attention, leading to delayed diagnosis.
Umi Kalsom Mohamad Yusof, Syamsiah Mashohor, Marsyita Hanafi, Sabariah Md Noor, Norsafina Zainal   +4 more
doaj   +1 more source